Finasteride and Masteron Interaction: Avoid | Peptide Database

FDA-approved for treatment of essential hypertension as monotherapy or in combination with other antihypertensives. Provides consistent 24-hour blood pressure reduction. Particularly effective for AAS-induced hypertension where elevated blood pressure is driven by RAAS activation and increased erythropoiesis. FDA-approved for reduction of cardiovascular morbidity in patients at high risk. The ONTARGET trial demonstrated non-inferiority to ramipril for the composite of cardiovascular death, MI, stroke, and hospitalization for heart failure in over 25,000 high-risk patients. Angiotensin II receptor blockade counteracts the pro-hypertrophic and pro-fibrotic effects of supraphysiological androgen levels on the myocardium. Preclinical and observational data support the use of ARBs to attenuate left ventricular hypertrophy in steroid users. Widely recommended in harm reduction protocols. Reduces intraglomerular pressure and proteinuria by blocking angiotensin II-mediated efferent arteriolar constriction. Slows progression of chronic kidney disease, particularly in patients with diabetic nephropathy or hypertensive nephrosclerosis. Relevant for AAS users where elevated blood pressure and NSAID co-use may compromise renal function. Telmisartan's partial PPAR-gamma agonism improves insulin sensitivity without the weight gain associated with full PPAR-gamma agonists like pioglitazone. May reduce the risk of new-onset diabetes in hypertensive patients. The metabolic benefit is particularly relevant for users of compounds that impair glucose tolerance (e.g., growth hormone, trenbolone).

Join others researching Propranolol — share findings, ask questions, and learn from real experiences Propranolol is a non-selective beta-adrenergic receptor antagonist (beta blocker) and one of the oldest and most widely prescribed drugs in its class. FDA-approved since 1967 and marketed as Inderal, it blocks both beta-1 receptors in the heart (reducing heart rate, contractility, and cardiac output) and beta-2 receptors in the bronchial and vascular smooth muscle. In the performance-enhancing drug community, propranolol serves two primary roles: managing elevated resting heart rate caused by compounds such as trenbolone and clenbuterol, and controlling performance anxiety or situational anxiety symptoms. Trenbolone is notorious for raising resting heart rate and causing nocturnal tachycardia, while clenbuterol directly stimulates beta-2 receptors to increase heart rate as part of its sympathomimetic action. Propranolol's non-selective beta blockade makes it effective against both mechanisms. Its rapid onset (within 30-60 minutes of oral dosing) and relatively short duration of action make it well-suited for as-needed use, though it can also be dosed regularly for sustained heart rate control throughout an AAS cycle. Propranolol competitively blocks both beta-1 and beta-2 adrenergic receptors. Beta-1 blockade in the sinoatrial node and myocardium reduces heart rate (negative chronotropy), decreases the force of cardiac contraction (negative inotropy), and slows atrioventricular conduction (negative dromotropy). This directly counteracts the tachycardia induced by sympathomimetic compounds like clenbuterol and the unexplained heart rate elevation commonly reported with trenbolone use. Beta-2 blockade in peripheral vasculature contributes to a modest increase in peripheral vascular resistance initially, though chronic use leads to a net reduction in blood pressure through decreased cardiac output and suppression of renin release from the juxtaglomerular cells. Propranolol is highly lipophilic, readily crossing the blood-brain barrier, which accounts for its efficacy in managing anxiety symptoms, essential tremor, and the physical manifestations of sympathetic nervous system activation (tremor, palpitations, sweating). This central penetration also explains why propranolol is more effective for anxiety-related indications than hydrophilic beta blockers like atenolol. The drug undergoes extensive first-pass hepatic metabolism via CYP2D6 and CYP1A2, resulting in variable bioavailability (approximately 25-35%).